Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced the successful completion of its partnering visit to China from 13-17 May, 2024.
The week-long visit, led by CEO Juha Yrjänheikki and COO Laurent Decory, was aimed at strengthening partnerships and exploring potential investment opportunities in one of the world’s largest pharmaceutical markets. During the visit, the Aurealis Therapeutics team had the pleasure of meeting with esteemed partners Xbiome, Lynx Financial and Huahai Pharma. The team was deeply impressed by the experience, capabilities, infrastructure, and state-of-the-art facilities of their partners, who specialize in various fields including cell & gene therapies, microbiomes, live biotherapeutics, and artificial intelligence.
“This was a fantastic opportunity to meet our partners in person after years of remote collaboration. We were delighted to witness firsthand the expertise and dedication of our partners. Following IND approval, we are working closely with Xbiome team to ensure a smooth start of a Phase-2 study with AUP-16 to be conducted in China with DFU patients. ” said Juha Yrjänheikki, CEO of Aurealis Therapeutics.
In addition to reinforcing current partnerships, the visit also allowed Aurealis Therapeutics to explore new opportunities for collaboration and expansion in the vibrant and constantly growing Chinese market, in particular with CDMOs with impressive capabilities. Exploring cities like Shenzhen, Shanghai, and Suzhou provided the Aurealis team with unique insights into Chinese hospitality and culture.
Aurealis Therapeutics remains committed to its mission of improving the lives of millions of patients suffering from chronic wounds, cancer, and beyond. The successful conclusion of the partnering week in China marks an important milestone in the company’s journey towards advancing innovative therapies for unmet medical needs.
About AUP-16
AUP-16 is a genetically engineered Lactococcus Cremoris, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF2, bFGF), interleukin-4 (IL4) and macrophage colony stimulating factor (CSF1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com
